This is the authors' abstract. We don't add key points for this paper.
Preeclampsia is a devastating pregnancy-associated hypertensive syndrome. Although it is quite common, the pathophysiology of preeclampsia is not yet clear and remains “a disease of theory”. Angiogenic defect hypotheses have been intensively investigated, and some biomarkers have been independently analyzed as pathogenic clinical target molecules without direct proof of their roles in preeclampsia. In this review, we assessed an up-to-date list of proposed angiogenic defects for their relevance to preeclampsia. In addition, we introduce our working hypothesis of preeclampsia pathophysiology, which involves interactions between metabolic and angiogenic defects.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kanasaki et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: